赛升药业(300485) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of approximately ¥13.77 million for 2025, compared to a loss of ¥68.85 million in the same period last year, indicating a turnaround [5]. - The net profit excluding non-recurring gains and losses is projected to be approximately -¥28.69 million, a decrease of 299.58% compared to -¥23.47 million last year [5]. - The increase in net profit is primarily due to a rise in fair value changes of financial assets and investment income from joint ventures, estimated at ¥19 million, representing a 110% increase [7]. - The company anticipates non-recurring gains and losses to impact net profit by approximately ¥43 million, mainly from fair value changes and investment income from trading financial assets [8]. - The financial data presented is preliminary and has not been audited, with detailed figures to be disclosed in the 2025 annual report [9].